Efficient generation of clinical-grade genetically modified dendritic cells for presentation of multiple tumor-associated proteins

Transfusion

Volumn 50, Issue 4, 2010, Pages 831-842

  Garritsen, Henk S P ^a,b   MacKe, Lars ^a,b   Meyring, Wilhelm ^a,b   Hannig, Horst ^a,b   Pägelow, Ute ^a,b   Wörmann, Bernhard ^a,b   Geffers, Robert ^a,b   Dittmar, Kurt E J ^a,b   Lindenmaier, Werner ^a,b  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GREEN FLUORESCENT PROTEIN; HLA A ANTIGEN; TUMOR ANTIGEN;

ADENOVIRUS; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD DONOR; CD14+ CELL; CELL MATURATION; CONTROLLED STUDY; CRYOPRESERVATION; CYTOMETRIC BEAD ASSAY; CYTOMETRY; DENDRITIC CELL; DNA MODIFICATION; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENETIC TRANSDUCTION; GENETICALLY MODIFIED DENDRITIC CELL; HUMAN; LEUKAPHERESIS; MELANOMA; MONONUCLEAR CELL; PROTEIN EXPRESSION; QUALITY CONTROL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD19; CELL SURVIVAL; DENDRITIC CELLS; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; ORGANISMS, GENETICALLY MODIFIED; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; VACCINATION;

EID: 77950220484     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02519.x     Document Type: Article

References (55)

1. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003 15 : 138 47.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 392 : 245 52.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 10 : 909 15.
4. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999 96 : 2233 8.
5. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007 7 : 19 30.
6. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan K, Lew AM, Shortman K, Heath WR, Carbone FR. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006 25 : 153 62.
7. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997 9 : 10 6.
8. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A 1996 93 : 2588 92.
9. Araki H, Katayama N, Mitani H, Suzuki H, Nishikawa H, Masuya M, Ikuta Y, Hoshino N, Miyashita H, Nishii K, Minami N, Shiku H. Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. Br J Haematol 2001 114 : 681 9.
10. Putz T, Gander H, Ramoner R, Zelle-Rieser C, Rahm A, Nussbaumer W, Bartsch G, Höltl L, Thurnher M. Generation of clinical-grade monocyte-derived dendritic cells using the CliniMACS system. Methods Mol Med 2005 109 : 71 82.
11. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kämpgen E, Bender A, Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999 223 : 1 15.
12. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997 27 : 3135 42.
13. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007 449 : 419 26.
14. Doan T, Herd KA, Lambert PF, Fernando GJ, Street MD, Tindle RW. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res 2000 60 : 2810 5.
15. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000 191 : 795 804.
16. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, Kämpgen E, Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999 190 : 1669 78.
17. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000 191 : 1699 708.
18. Philip R, Alters SE, Brunette E, Ashton J, Gadea J, Yau J, Lebkowski J, Philip M. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma. J Immunother 2000 23 : 168 76.
19. Lundqvist A, Choudhury A, Nagata T, Andersson T, Quinn G, Fong T, Maitland N, Pettersson S, Paulie S, Pisa P. Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther 2002 13 : 1541 9.
20. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 2001 97 : 114 21.
21. Strobel I, Krumbholz M, Menke A, Hoffmann E, Dunbar PR, Bender A, Hobom G, Steinkasserer A, Schuler G, Grassmann R. Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector. Hum Gene Ther 2000 11 : 2207 18.
22. Van Tendeloo VF, Snoeck HW, Lardon F, Vanham GL, Nijs G, Lenjou M, Hendriks L, Van Broeckhoven C, Moulijn A, Rodrigus I, Verdonk P, Van Bockstaele DR, Berneman ZN. Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells. Gene Ther 1998 5 : 700 7.
23. Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, Green S, Miloradovic L, Drane D, Davis ID, Villadangos J, Shortman K, Maraskovsky E, Cebon J. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005 105 : 2465 72.
24. Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 2001 166 : 3678 87.
25. Langenkamp A, Casorati G, Garavaglia C, Dellabona P, Lanzavecchia A, Sallusto F. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol 2002 32 : 2046 54.
26. Dietz AB, Vuk Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998 91 : 392 8.
27. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 2003 170 : 2912 22.
28. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappaB (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. J Immunol 2003 171 : 4121 30.
29. Pullarkat V, Lau R, Lee SM, Bender JG, Weber JS. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods 2002 267 : 173 83.
30. Curti A, Isidori A, Ferri E, Terragna C, Neyroz P, Cellini C, Ratta M, Baccarani M, Lemoli RM. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Leuk Lymphoma 2004 45 : 1419 28.
31. Buchler T, Kovarova L, Musilova R, Bourková L, Ocadlíková D, Buliková A, Hanák L, Michálek J, Hájek R. Generation of dendritic cells using cell culture bags - description of a method and review of literature. Hematology 2004 9 : 199 205.
32. Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kämpgen E, Schuler G, Schuler-Thurner B. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 2007 30 : 663 74.
33. Graham FL, Prevec L. Manipulation of adenovirus vectors. In : Murray EJ, editor. Gene transfer and expression protocols. Clifton (NJ) : Humana Press 1991 109 29.
34. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996 70 : 7498 509.
35. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994 24 : 759 64.
36. Britten CM, Meyer RG, Graf C, Huber C, Wolfel T. Identification of T cell epitopes by the use of rapidly generated mRNA fragments. J Immunol Methods 2005 299 : 165 75.
37. Macke L, Garritsen HSP, Meyring W, Hannig H, Pägelow U, Wörmann B, Piechaczek C, Geffers R, Rohde M, Lindenmaier W, Dittmar KEJ. Evaluating maturation and genetic modification of human dendritic cells in a new polyolefin cell culture bag system. Transfusion 2010 50 : 843 55.
38. Dietz AB, Bulur PA, Knutson GJ, Matasić R, Vuk-Pavlović S. Maturation of human monocyte-derived dendritic cells studied by microarray hybridization. Biochem Biophys Res Commun 2000 275 : 731 8.
39. Hashimoto S, Suzuki T, Dong HY, Nagai S, Yamazaki N, Matsushima K. Serial analysis of gene expression in human monocyte-derived dendritic cells. Blood 1999 94 : 845 52.
40. Rouard H, Leon A, Klonjkowski B, Marquet J, Tennezé L, Plonquet A, Agrawal SG, Abastado JP, Eloit M, Farcet JP, Delfau-Larue MH. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods 2000 241 : 69 81.
41. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999 29 : 964 72.
42. Tiefenthaler M, Marksteiner R, Neyer S, Koch F, Hofer S, Schuler G, Nussenzweig M, Schneider R, Heufler C. M1204, a novel 2′,5′ oligoadenylate synthetase with a ubiquitin-like extension, is induced during maturation of murine dendritic cells. J Immunol 1999 163 : 760 5.
43. Hartmann R, Olsen HS, Widder S, Jørgensen R, Justesen J. p59OASL, a 2′-5′ oligoadenylate synthetase like protein: a novel human gene related to the 2′-5′ oligoadenylate synthetase family. Nucleic Acids Res 1998 26 : 4121 8.
44. Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad H, Tierens A, Kvalheim G. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand J Immunol 2003 58 : 578 86.
45. Guyre CA, Fisher JL, Waugh MG, Wallace PK, Tretter CG, Ernstoff MS, Barth RJ Jr. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods 2002 262 : 85 94.
46. Campbell-Anson RE, Kentor D, Wang YJ, Bushnell KM, Li Y, Vence LM, Radvanyi LG. A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology. J Immune Based Ther Vaccines 2008 6 : 1.
47. Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002 264 : 135 51.
48. Wong EC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, Kopp W, Mackall CL, Berzofsky J, Read EJ. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001 3 : 19 29.
49. Sonderbye L, Feng S, Yacoubian S, Buehler H, Ahsan N, Mulligan R, Langhoff E. In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction. Exp Clin Immunogenet 1998 15 : 100 11.
50. Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001 166 : 5236 44.
51. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002 7 : 46 59.
52. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006 208 : 299 318.
53. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002 13 : 3 13.
54. Teichler ZD. US gene therapy in crisis. Trends Genet 2000 16 : 272 5.
55. Yang S, Kittlesen D, Slingluff CL Jr., Vervaert CE, Seigler HF, Darrow TL. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. J Immunol 2000 164 : 4204 11.